Literature DB >> 1647966

Inhibition of sympathetic nerve activity by acute administration of the tricyclic antidepressant desipramine.

G Lavian1, G Di Bona, J P Finberg.   

Abstract

In rats anesthetized with pentobarbital/chloral hydrate, the i.v. injection of desipramine (0.3 mg/kg) caused a rapid fall in mean arterial blood pressure accompanied by a reduction in efferent renal nerve integrated activity. A similar reduction in electrical activity was seen in the preganglionic splanchnic nerve. Pretreatment of the rats with yohimbine (0.3 mg/kg) increased renal nerve activity by 20%, and the decrease in blood pressure and renal nerve activity elicited by a subsequent dose of desipramine was blocked. I.v. injection of prazosin (0.05 mg/kg) caused a reduction in systemic blood pressure. The hypotensive effect of a subsequent dose of desipramine was largely blocked, whereas the fall in renal nerve activity was attenuated, but still present. The data are consistent with an action of desipramine to reduce central sympathetic tone by increasing the release of endogenous noradrenaline which acts on alpha 2-adrenoceptors at CNS sites controlling sympathetic activity. An additional involvement of central alpha 1-adrenoceptors cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647966     DOI: 10.1016/0014-2999(91)90099-c

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  New therapies for postural hypotension.

Authors:  Michael G Ziegler; Milos Milic
Journal:  Hypertension       Date:  2012-02-06       Impact factor: 10.190

2.  Determining the subjective and physiological effects of BZP on human females.

Authors:  Joanne C Lin; Nisha Bangs; Heeseung Lee; Rob R Kydd; Bruce R Russell
Journal:  Psychopharmacology (Berl)       Date:  2009-09-24       Impact factor: 4.530

3.  Inhibition of uptake 1 by (+)-oxaprotiline reveals a differential central regulation of noradrenaline and adrenaline release.

Authors:  B Szabo; T Auberle; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-09       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.